Clinical trials: Rosuvastatin
Obesity or Overweight
Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of GZR18 Injection on gastric emptying and the effect of repeated SC injections of GZR18 Injection on the pharmacokinetics of oral…
- Trial name
- NCT07128888
- Testing
- GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Gan & Lee Pharmaceuticals.
HIV Infections
Study on Pharmacokinetics
The purpose of this study is to assess the effect of the coadministration of multiple doses of BMS-663068 on the systemic exposure of rosuvastatin.
- Trial name
- NCT02234882
- Testing
- Rosuvastatin, BMS-663068
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy
This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men
The primary objective of this trial is to investigate the relative bioavailabilities of digoxin, furosemide, metformin and rosuvastatin given as a cocktail alone and as a cocktail together with the following drug transporter…
- Trial name
- NCT03307252
- Testing
- Digoxin, Furosemide, Metformin
- Where
- Germany
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Malaria
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir
The purpose of this study is to assess the effect of multiple doses of ganaplacide and lumefantrine combination on the substrates of cytochrome P450 (CYP) 3A4 (midazolam), CYP2C8 (repaglinide), CYP2D6 (dextromethorphan), organic…
- Trial name
- NCT05236530
- Testing
- Midazolam, Repaglinide, Dextromethorphan
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Hyperlipidemia
Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets
To evaluate the efficacy and the safety of concomitant use of Ezetimibe/Rosuvastatin combination tablets and Candesartan cilexetil/Amlodipine besylate combination tablets compared to each combination tablet alone in patients with…
- Trial name
- REVERT-K (NCT03847506)
- Testing
- Ezetimibe/Rosuvastatin, Candesartan cilexetil/Amlodipine besylate, Candesartan cilexetil
- Where
- South Korea
- Volunteers
- 127 people
- Sponsor
- HK inno.N Corporation
Advanced Solid Tumor, Metastatic Solid Tumor
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
This is a Phase 1 study to evaluate the potential drug-drug interaction (DDI) effect of repotrectinib on certain drug transporters in patients with advanced cancer.
- Trial name
- NCT05828303
- Testing
- TPX-0005, Metformin Hydrochloride, Digoxin
- Where
- 33 sites in United States, Australia and 4 more
- Sponsor
- Turning Point Therapeutics, Inc.
Hypercholesterolaemia
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
The purpose of this study is to compare the effectiveness and safety of rosuvastatin 5mg in lowering blood cholesterol, compared to one other medicine, atorvastatin 10mg in Asian patients in the UK.
- Trial name
- NCT00427960
- Testing
- Dietary advice, rosuvastatin, atorvastatin
- Where
- 9 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease
A Study to Learn More About How Safe Nurandociguat is and How it Affects the Way the Body Processes Rosuvastatin and Dabigatran in Healthy Adults
Researchers are looking for a better way to treat people who have chronic kidney disease. Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work as well as they should.
- Trial name
- NCT07515339
- Testing
- Nurandociguat, Rosuvastatin, Dabigatran etexilate
- Where
- Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects
This study is designated to evaluate the pharmacokinetic interactions of amlodipine besylate, valsartan and rosuvastatin in healthy male volunteers.
- Trial name
- NCT02060019
- Testing
- administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Healthy Volunteer Study
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin
Drug-drug interaction study between Bemnifosbuvir/Ruzasvir and Digoxin or Rosuvastatin
- Trial name
- NCT06921941
- Testing
- Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR, Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR
- Where
- Canada
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Dyslipidemia
Observational Study To Evaluate Statins Patterns Of Use In Spain
The present project is aimed at describing the statins prescription pattern in Spanish patients. It will also look into how adequate these prescriptions are accordingly to the recommendations given in Treatment Guidelines and in…
- Trial name
- NCT01023503
- Where
- Spain
- Sponsor
- AstraZeneca
Hypertension, Hyperlipidemia
Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia
Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate efficacy and safety of co-administrated temisartan/amlodipine and rosuvastatin in subjects with hypertension and hyperlipidemia.
- Trial name
- NCT03067688
- Testing
- Temisartan+Amlodipine+Rosuvastatin (Combination drug), Temisartan+Amlodipine, Temisartan+Rosuvastatin
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Yuhan Corporation
Primary Hypercholesterolemia, Hypertension
To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
This study is a multicenter, Randomized, double-blind, acitve-controlled, Phase 3 Clinical Trial in 8 weeks for screening, twice Investigational product administer, Follow up visit.
- Trial name
- NCT04659070
- Testing
- Experimental : Ezetimibe / Rosuvastatin + Telmisartan, Active comparator1 : Ezetimibe / Rosuvastatin, Active comparator2 : Telmisartan
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Hypercholesterolemia
Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal
The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol…
- Trial name
- NCT00240344
- Where
- 75 sites in Netherlands
- Volunteers
- 2,650 people
- Sponsor
- AstraZeneca
Healthy
Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants
This is a Phase 1, randomized, 2 way crossover, multiple dose, open label study of the effect of PF 04965842 on rosuvastatin PK in healthy participants. Participants will be randomized to 1 of the 2 treatment sequences.
- Trial name
- NCT03806101
- Testing
- PF-04965842, Rosuvastatin
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Evaluating of Pharmacokinetic Profile of BCWP_C003 and Co-administration of Rosuvastatin and Metformin
The purpose of this study is to evaluate the pharmacokinetic Profile and Safety/Tolerability of BCWP_C003 compared to Co-Administration of Crestor 10mg and Glucophage XR 1000mg, and to evaluate the food effect of Pharmacokinetic…
- Trial name
- NCT01992211
- Testing
- Rosuvastatin, Metformin, BCWP_C003
- Where
- South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- BC World Pharm Co. Ltd.
Healthy
A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects
This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262
- Trial name
- NCT05763459
- Testing
- ABBV-CLS-7262
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Calico Life Sciences LLC
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
An open-label, randomized, single-dose, 2X3X3 partial replicate, crossover study to compare the pharmacokinetics and safety between a fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a fixed…
- Trial name
- NCT02995720
- Testing
- Fimasartan/Amlodipine combination drug, Rosuvastatin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Primary Hypercholesterolemia
Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting
This study assessed the safety and efficacy of generic Rosuvastatin in reducing plasma low density lipoprotein (LDL) cholesterol in Lebanese adult patients (18 years or older) with dyslipidemia for both primary and secondary…
- Trial name
- NCT03516955
- Testing
- Rosuvastatin
- Volunteers
- 317 people
- Sponsor
- Hikma Pharmaceuticals LLC
Hypertension, Hyperlipidemia
Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg
To compare the safety and pharmacokinetics between ROVATITAN tab. 160/20 mg (ROVATITAN tab 160/20mg-1, ROVATITAN tab. 160/20mg-2) and coadministration of Diovan® (Valsartan) 160 mg and Crestor® (Rosuvastatin) 20 mg in healthy…
- Trial name
- NCT01918358
- Testing
- Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R), Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1), Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences